PTIL » Topics » Research and Development

This excerpt taken from the PTIL 6-K filed Nov 20, 2008.

Research and Development

As planned, R&D expenditure increased to £9.7 million in the half year, from £8.6 million in the prior year, as the Company continued to progress its development pipeline. Significant effort has continued to support Voraxaze marketing submission in the US. In addition, we continue the investment in OncoGel, Prolarix, CoVaccine HT and Angiotensin Therapeutic Vaccine to support the ongoing phase 2 studies.
 

This excerpt taken from the PTIL 6-K filed Nov 23, 2007.

Research and Development

 

As planned, R&D expenditure has increased significantly to £8.6 million in the half year from £7.1 million as we have invested in our expanded development pipeline. Significant effort has continued on scaling up the CytoFab manufacturing process and on Voraxaze to support planned regulatory filings. In addition, work has commenced on the manufacture of Prolarix™, CoVaccine HT™ and Angiotensin Therapeutic Vaccine to support the forthcoming phase 2 studies.
 

This excerpt taken from the PTIL 6-K filed Dec 7, 2006.

Research and Development

As planned, R&D expenditure has increased significantly to £7.1 million in the half year from £2.4 million as work is well under way on developing and scaling up the CytoFab manufacturing process. In addition, spending continued on Voraxaze to support regulatory filings, and on Prolarix and Angiotensin Therapeutic Vaccine.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki